Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia
Individuals with chronic lymphocytic leukemia (CLL) have significant immune disfunction, often further disrupted by treatment. While currently available COVID-19 vaccinations are highly effective in immunocompetent individuals, they are often poorly immunogenic in CLL patients. It is important to un...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/6831640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565602506506240 |
|---|---|
| author | Zoe L. Lyski Myung Sun Kim David Xthona Lee David Sampson Hans-Peter Raué Vikram Raghunathan Debbie Ryan Amanda E. Brunton Mark K. Slifka William B. Messer Stephen E. Spurgeon |
| author_facet | Zoe L. Lyski Myung Sun Kim David Xthona Lee David Sampson Hans-Peter Raué Vikram Raghunathan Debbie Ryan Amanda E. Brunton Mark K. Slifka William B. Messer Stephen E. Spurgeon |
| author_sort | Zoe L. Lyski |
| collection | DOAJ |
| description | Individuals with chronic lymphocytic leukemia (CLL) have significant immune disfunction, often further disrupted by treatment. While currently available COVID-19 vaccinations are highly effective in immunocompetent individuals, they are often poorly immunogenic in CLL patients. It is important to understand the role a heterologous boost would have in patients who did not respond to the initial two-dose mRNA vaccine series. SARS-CoV-2 specific immune responses, including antibodies and memory B-cells, CD4 and CD8 T-cells were assessed prior to vaccination, as well as postinitial vaccination series and post-third dose in two subjects. One subject seroconverted, had RBD-specific memory B-cells and spike-specific CD4 T-cells while the other did not. Both subjects had a spike-specific CD8 T-cell response after the original mRNA vaccination series that was further boosted after the third dose or remained stable. The results of this study, however small, are especially promising to CLL individuals who did not seroconvert following the initial mRNA vaccination series. |
| format | Article |
| id | doaj-art-b0a143a3e32d4a6fbe0d76b253bb0eb8 |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-b0a143a3e32d4a6fbe0d76b253bb0eb82025-02-03T01:07:10ZengWileyCase Reports in Hematology2090-65792022-01-01202210.1155/2022/6831640Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic LeukemiaZoe L. Lyski0Myung Sun Kim1David Xthona Lee2David Sampson3Hans-Peter Raué4Vikram Raghunathan5Debbie Ryan6Amanda E. Brunton7Mark K. Slifka8William B. Messer9Stephen E. Spurgeon10Department of Molecular Microbiology & ImmunologyKnight Cancer InstituteDepartment of Molecular Microbiology & ImmunologyKnight Cancer InstituteDivision of NeuroscienceKnight Cancer InstituteKnight Cancer InstituteOHSU-PSU School of Public HealthDivision of NeuroscienceDepartment of Molecular Microbiology & ImmunologyKnight Cancer InstituteIndividuals with chronic lymphocytic leukemia (CLL) have significant immune disfunction, often further disrupted by treatment. While currently available COVID-19 vaccinations are highly effective in immunocompetent individuals, they are often poorly immunogenic in CLL patients. It is important to understand the role a heterologous boost would have in patients who did not respond to the initial two-dose mRNA vaccine series. SARS-CoV-2 specific immune responses, including antibodies and memory B-cells, CD4 and CD8 T-cells were assessed prior to vaccination, as well as postinitial vaccination series and post-third dose in two subjects. One subject seroconverted, had RBD-specific memory B-cells and spike-specific CD4 T-cells while the other did not. Both subjects had a spike-specific CD8 T-cell response after the original mRNA vaccination series that was further boosted after the third dose or remained stable. The results of this study, however small, are especially promising to CLL individuals who did not seroconvert following the initial mRNA vaccination series.http://dx.doi.org/10.1155/2022/6831640 |
| spellingShingle | Zoe L. Lyski Myung Sun Kim David Xthona Lee David Sampson Hans-Peter Raué Vikram Raghunathan Debbie Ryan Amanda E. Brunton Mark K. Slifka William B. Messer Stephen E. Spurgeon Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia Case Reports in Hematology |
| title | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia |
| title_full | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia |
| title_fullStr | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia |
| title_full_unstemmed | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia |
| title_short | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia |
| title_sort | immunogenicity of pfizer mrna covid 19 vaccination followed by j j adenovirus covid 19 vaccination in two patients with chronic lymphocytic leukemia |
| url | http://dx.doi.org/10.1155/2022/6831640 |
| work_keys_str_mv | AT zoellyski immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT myungsunkim immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT davidxthonalee immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT davidsampson immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT hanspeterraue immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT vikramraghunathan immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT debbieryan immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT amandaebrunton immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT markkslifka immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT williambmesser immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia AT stephenespurgeon immunogenicityofpfizermrnacovid19vaccinationfollowedbyjjadenoviruscovid19vaccinationintwopatientswithchroniclymphocyticleukemia |